Cipla In-Licenses MSD's Isentress HIV/AIDS Drug To Market In India
This article was originally published in PharmAsia News
Executive Summary
Cipla and Merck’s MSD unit have signed a commercialization agreement that would give the India drug maker rights to Isentress (raltegravir), a leading third-line HIV/AIDS treatment.